The cohort was enriched in breast cancer patients with low RAS gene signature (a score derived from expression of 147 transcripts) or ER+ patients with high Ki-67 index (high proliferation).40 Partial and complete response were observed in 12.5% and 14.3% of the patients, respectively. Here, ESR1 is linked to breast carcinoma.